Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2025-12-25 @ 9:26 PM
Study NCT ID:
NCT06227156
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-01-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Sponsor:
RemeGen Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-08
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-17
First Submit QC Date:
None
Study First Post Date:
2024-01-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-21
Last Update Post Date:
2024-05-23
Last Update Post Date Type:
ACTUAL